JPET Fast Forward. Published on November 10, 2011 as DOI:10.1124/jpet.111.186296

Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluorothymidine, a novel antitumor nucleoside, in rats

Takashige Okayama, Kunihiro Yoshisue, Keizo Kuwata, Masahito Komuro, Shigeru Ohta, Sekio Nagayama

Tokushima research center, Taiho Pharmaceutical Co., Ltd, Tokushima, Japan (T.O., K.Y., K.K., M.K., S.N.)

Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan (T.O., S.O.)

Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics.

Running title page

a) Running title

Involvement of CNT1 in intestinal absorption of TFT

b) Corresponding author

Name: Takashige Okayama

Address: 224-2 Ebisuno, Hiraishi, Kawauchi-cho, Tokushima 771-0194, Japan

Telephone number: +81-88-665-5337

Fax number: +81-88-665-6206

E-mail address: t-okayama@taiho.co.jp

c) the number of text pages : 35

the number of table : 1

the number of figures : 10

the number of references : 24

words in the abstract : 245

words in the Introduction : 494

words in the Discussion : 692

D) Abbreviations

CNT, concentrative nucleoside transporter; cRNA, complementary RNA; ENT, equilibrative nucleoside transporter; 5-FU, 5-fluorouracil; hCNT3, human CNT3; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HPLC, high performance liquid chromatography; HPMC, hydroxypropylmethylcellulose; MBS, Modified Barth's Solution; rCNT1, rat CNT1; rCNT2, rat CNT2; rCNT3, rat CNT3; SEM, standard error of the mean; SD, standard deviation; TFT, ααα-trifluorothymidine; TS, thymidylate synthase; TP, thymidine phosphorylase; TPI, thymidine phosphorylase inhibitor

Abstract

ααα-Trifluorothymidine (TFT), an anticancer nucleoside analogue, is a potent thymidylate synthase (TS) inhibitor. TFT exerts its antitumor activity primarily by inducing DNA fragmentation after incorporation of the triphosphate form of TFT into the DNA. Although an oral combination of TFT and a thymidine phosphorylase inhibitor (TPI) has been clinically developed, there is little information regarding TFT absorption. Therefore, we investigated TFT absorption in the rat small intestine. After oral administration of TFT in rats, more than 75% of the TFT was absorbed. To identify the uptake transport system, uptake studies were conducted by using everted sacs prepared from rat small intestines. TFT uptake was saturable, significantly reduced under Na^+-free conditions, and strongly inhibited by the addition of an endogenous pyrimidine nucleoside. From these results, we suggested the involvement of concentrative nucleoside transporters (CNTs) in TFT absorption into rat small intestine. In rat small intestines, the mRNAs coding for rat CNT1 (rCNT1) and rCNT2, but not for rCNT3, were predominantly expressed. To investigate the roles of rCNT1 and rCNT2 in TFT uptake, we conducted uptake assays by using *Xenopus laevis* oocytes injected with rCNT1 complementary RNA (cRNA) and rCNT2 cRNA. TFT uptake by *Xenopus* oocytes injected with rCNT1 cRNA, and not rCNT2 cRNA, was significantly greater than that by

water-injected oocytes. Additionally, *in situ* single-pass perfusion experiments performed using rat jejunum regions showed that thymidine, a substrate for CNT1, strongly inhibited TFT uptake. In conclusion, TFT is absorbed via rCNT1 in the intestinal lumen in rats.

Introduction

ααα-Trifluorothymidine (TFT, Fig 1), an anticancer nucleoside analogue, is a potent thymidylate synthase (TS) inhibitor similar to 5-fluorouracil (5-FU). TFT exerts its antitumor activity primarily by inducing DNA fragmentation after the triphosphate form of TFT is incorporated into DNA (Emura, 2004; Temmink, 2005). Initial clinical studies showed promising antitumor activity of TFT, with >50% tumor shrinkage after bolus intravenous administration of TFT in patients with colorectal and breast cancers (Ansfield, 1971). However, TFT is rapidly degraded ($t_{1/2}$, 12 to 18 min) by thymidine phosphorylase (TP), and initial high plasma concentrations of TFT cause significant bone marrow toxicity (Ansfield, 1971). Therefore, intravenous administration of TFT cannot be performed in clinical anticancer chemotherapy (Dexter, 1972). However, a combination of TFT and 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1*H*,3*H*)-pyrimidinedione hydrochloride, a competitive inhibitor of TP (TPI) without any intrinsic antitumor activity, at a molecular ratio of 1:1, results in retention of the effective concentration of TFT in the blood for a prolonged period after oral administration. An oral formulation of a combination of TFT and TPI has been clinically developed (Hong, 2006; Overman 2008).

The small intestine is the primary absorption site for many orally administered drugs. Intestinal absorption mainly occurs via 2 mechanisms: passive diffusion and carrier-mediated transport. Carrier-mediated transport plays an important role in small intestinal absorption of some drugs, especially those with low permeability and high solubility such as TFT. Nucleoside transporters (NTs) that are also expressed on the surfaces of epithelial cells in the intestine have been characterized in the carrier-mediated transport of nucleoside analogues. These NTs include concentrative nucleoside transporters (CNTs) and equilibrative nucleoside transporters (ENTs). CNTs facilitate sodium-dependent uptake of substrates into cells, and 3 isoforms of CNTs (CNT1, CNT2, and CNT3) have been identified; CNT1 and CNT2 primarily act to translocate pyrimidine and purine nucleosides, respectively, via a sodium-dependent mechanism, whereas CNT3 shows broad substrate selectivity and the unique ability of translocating nucleosides via both sodium- and proton-coupled mechanisms (Smith, 2005). These transporters are involved in the membrane permeability of not only endogenous nucleosides but also some nucleoside analogues (Lang, 2001; Mackey, 1999; Ritzel, 2001); in addition, these transporters are involved in the absorption of the drugs such as ribavirin (Patil, 1998) and mizoribine (Okada, 2006; Mori, 2008). CNTs are also predominantly expressed in various other mammalian tissues and cancer cells (Pennycooke, 2001;

Hong Lu, 2004; Govindarajan, 2007). Therefore, CNTs are known to be involved in not only the pharmacokinetics but also the clinical effect of nucleoside analogues (Maréchal, 2009). Furthermore, CNTs are expected to serve as prospective biomarkers for the clinical effect of nucleoside drugs.

The purpose of this study was to identify the mechanism of TFT absorption in the small intestine because there is little information regarding TFT absorption. We investigated TFT absorption in the small intestine of rats and characterized the rat NT that accepts TFT as the substrate and identified the contribution of NTs in the small intestinal absorption of TFT that shows the type III character in BCS classification (Amidon, 1995).

Materials and Methods

Materials

^{14}C-TFT and unlabeled TFT were synthesized by Daiichi Pure chemicals (Tokyo, Japan) and Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan), respectively. ^{14}C-thymidine and ^{14}C-inosine were purchased from Moravek (Brea, CA). Unlabeled thymidine and inosine were obtained from Wako Pure Chemicals Industries Ltd. (Osaka, Japan). Uridine was purchased from Sigma Chemical Co. (St. Louis, MO, USA). ^{3}H-inulin was purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO, USA). 2,4-Dinitrophenol (2,4-DNP) and sodium azide (NaN_3) were purchased from Alfa Aesar (Karlsruhe, Germany) and Tokyo chemical Industry (Tokyo, Japan), respectively. Male Sprague–Dawley rats were purchased from Charles River Laboratories (Yokohama, Japan) and *Xenopus laevis* were purchased from Japan SLC (Hamamatsu, Japan). Other all reagents and solvents were reagent or HPLC grade.

Concentration of total radioactivity and ^{14}C-TFT in plasma

To evaluate the concentration of TFT in plasma, ^{14}C-TFT and TPI were dissolved in 0.5% hydroxypropylmethylcellulose (HPMC) solution and administered orally to rats by gavage. The

concentrations of TFT and TPI in dosing solution were 50 mg/ 3.7MBq/ 5mL/ kg and 23.6 mg/ 5 mL/ kg, respectively. After orally administration, blood samples were collected from the abdominal aorta and plasma was purified from each sample by centrifugation. The plasma was extracted with methanol, and the organic layer was dried under a nitrogen stream. The resultant residue was dissolved in the mobile phase (20 mM phosphate buffer (pH 7.2)/ acetonitrile : 96/4) and injected into the radio HPLC to evaluate the concentration of TFT in plasma.

Excretion in urine, feces, and expired air

To evaluate the concentration of total radioactivity in urine, feces, and expired air, ^{14}C-TFT and TPI were dissolved in 0.5% HPMC solution and administered orally to rats by gavage. The concentrations of ^{14}C-TFT and TPI in dosing solution were 50 mg/ 3.7MBq/ 5mL/ kg and 23.6 mg/ 5mL/ kg, respectively. After oral administration, the rats were placed individually in metabolism cages to collect urine and feces separately at specific time points. Radioactive carbon dioxide in expired air was collected using 20% 2-monoamine ethanol. Radioactivity in urine, expired air, and feces was determined using a liquid scintillation counter.

Uptake assays in intestinal everted sacs

Uptake assays were conducted using everted sacs (3 cm in length) prepared from the jejunum of male Sprague–Dawley rats by making a few modifications to a previously reported method (Nakashima, 1985; Kato, 2004). Briefly, everted sacs were pre-incubated for 5 min in oxygenated Krebs-Ringer bicarbonate buffer (Krebs buffer; 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH_2PO_4, 2.5 mM $CaCl_2$, 1.2 mM $MgSO_4$, and 25 mM $NaHCO_3$, pH 7.4) before the initiation of uptake experiments and incubated in a test solution at 37°C for 1 min. To prepare the test solution, ^{14}C-TFT and ^{3}H-inulin, a non-absorbable marker, were added in oxygenated Krebs buffer. The uptake experiment was terminated by rinsing the everted sacs twice in ice-cold saline. Uptake into tissues was evaluated by determining the radioactivity using a liquid scintillation counter after solubilization of the sample using a Soluen-350 (Perkin Elmer) as a tissue solubilizer and 10 mL of Hionic-flour (PerkinElmer) as scintillation fluid.

Preparation of total RNA, rCNT1 cDNA, and rCNT2 cDNA

Total RNA was extracted from rat intestinal mucosa by using RNA Later (Ambion, Austin, TX, USA) and an RNeasy Mini Kit (QIAGEN, Valencia, CA, USA). Total RNA was

reverse-transcribed into cDNA by using the TAKARA STAR™ RT PCR kit (TAKARA, Shiga, Japan).

An rCNT1 clone was obtained by amplifying the cDNA derived from rat small intestine mucosa by performing PCR with KOD Plus Polymerase (TOYOBO, Osaka, Japan). A 5′ primer (5′-ATGGCAGACAACACACAGAG-3′) and a 3′ primer (5′-CCAGCTATGTGCAGACTGTG-3′) derived from the reported sequence of rat CNT1 (NCBI gene bank) were used. The PCR product was inserted into pCRII-TOPO (Invitrogen, Carlsbad, CA, USA), and sequence analysis of the resulting pCRII-TOPO/rCNT1 vector was conducted by Hokkaido System Sciences (Hokkaido, Japan). The sequence of the amplified *CNT1* gene was confirmed to be identical to that in GenBank. Similarly, an rCNT2 clone was obtained by amplifying cDNA using PCR with KOD Plus Polymerase (TOYOBO, Osaka, Japan). A 5′ primer (5′-CACCCAGCACATTCAGAGGA-3′) and a 3′ primer (5′-AGAACTGTCACGGAATGGCC-3′) were used. The PCR product was subcloned into pENTR/D-TOPO (Invitrogen) and introduced into pEF-DEST51 (Invitrogen) using the Gateway LR Clonase Enzyme Mix (Invitrogen). Similar to rCNT1, sequence analysis of the pENTR/D-TOPO/rCNT1 vector was conducted by Hokkaido System Sciences, and the sequence of the amplified *CNT2* gene was confirmed to be identical to that in GenBank.

Uptake of TFT by *Xenopus laevis* oocytes

After linearization of the pCRII-TOPO vector/rCNT1 using *Pvu* I (TOYOBO, Osaka, Japan), capped cRNA of rCNT1 was synthesized using T7 RNA polymerase (Stratagene, Santa Clara, CA, USA). Similarly, after linearization of pEF-DEST51/rCNT2 using *Nae*I (TOYOBO, Osaka, Japan), cRNA of rCNT2 was also synthesized.

For uptake experiments, *Xenopus laevis* oocytes were prepared by manual dissection and the samples were treated with collagenase A (Wako, Osaka, Japan) in a calcium-free OR2 solution (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl, 5 mM HEPES, pH 7.5). Oocytes were washed and peeled in MBS (88 mM NaCl, 1 mM KCl, 0.33 mM $Ca(NO_3)_2$, 0.41 mM $CaCl_2$, 0.82 mM $MgSO_4$, 2.4 mM $NaHCO_3$, 10 mM HEPES, pH 7.4) and injected with 50 nL of cRNA or nuclease-free water. Oocytes were incubated for 3 days at 18°C in MBS containing 50 μg/mL gentamycin.

Three days after cRNA injection, oocytes were transferred to ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM $CaCl_2$, 1 mM $MgCl_2$, 5 mM HEPES, pH 7.4) and pre-incubated at 25°C for 5 min. Uptake was initiated by replacing the solution with fresh ND96 solution containing labeled substrate at 25°C, and at designated times, the oocytes were rinsed 5 to 6 times with ice-cold ND96 solution

and dissolved with soluen-350. The associated radioactivity was measured using a liquid scintillation counter.

***In situ* single-pass perfusion method**

Male Sprague–Dawley rats that had fasted overnight with free access to water were used for this procedure. Under anesthesia with sodium pentobarbital (Dainippon Sumitomo Pharma, Osaka, Japan), the upper jejunum region in rats was perfused with a test solution containing 0.4 μM ^{14}C-TFT and ^{3}H-inulin, a non-absorbable marker, in saline (Otsuka Pharmaceutical Industry, Naruto, Japan). Perfusion was carried out using a constant-infusion pump at a flow rate of 0.4 mL/min, and the perfusate was maintained at 37°C. After 20 min, to ascertain whether steady state had been achieved, 3 samples were collected at 5-min intervals. Residual substrate concentrations of these samples were measured using a liquid scintillation counter. The steady-state intestinal effective permeability (P_{eff} cm/s) was calculated according to the following formula, $P_{eff} = [-Q \times \ln (C_{out} / C_{in})]/2 (pi) rL$, where, Q is the flow rate (0.4 mL/min), C_{in} and C_{out} are the inlet and outlet perfusate concentrations, and the outlet concentration was corrected for water flux with ^{3}H-inulin . 2 (pi) rL is the cylindrical surface area of the intestinal segment with a length ‘L’ (approximately 15

cm) and ‘r’ (0.2 cm) is the intestinal radius.

Statistical analysis

Data are expressed as mean ± S.D. or means ± S.E.M. Student’s *t*-test was used for paired variates. An overall $p<0.05$ was considered significant.

Results

In vivo absorption of FTD in rats

As shown in Fig. 2, plasma concentration of TFT was measured after oral administration of ^{14}C-TFT and TPI to fasting rats. The T_{max} values and $t_{1/2}$ values of ^{14}C-TFT were 0.25 h and 0.49 h, respectively. Moreover**,** after oral administration of ^{14}C-TFT and TPI, accumulated radioactivity excreted in the urine, feces, and expired air were measured using a liquid scintillation counter. As shown in Table 1, 59.8, 19.7, and 15.6 % of radioactivity (% of dose) was excreted in the urine, feces, and expired air, respectively, within 24 h after dosing, and total radioactivity excretion was 95.0% of the dosed radioactivity within 24 h after dosing. On the basis of these results, the absorption ratio of TFT in rats was estimated to be more than 75% of the dose.

Uptake of TFT in the everted sacs

To clarify the uptake mechanisms from the small intestinal lumen in rats, uptake studies using everted sacs were conducted. Uptake rates of TFT in the small intestine were saturable with regard to substrate concentration, as shown in Fig. 3a. An Eadie–Hofstee plot showed biphasic behavior in the small intestine, as shown in Fig. 3b, indicating the presence of high- and low-affinity

uptake systems. To identify the active uptake transport system of TFT, the inhibitory effects of Na^+, pyrimidine nucleosides, 2, 4-DNP and NaN_3 on TFT uptake were evaluated. Pyrimidine nucleosides were endogenous substrates of nucleoside transporters such as CNTs, and NaN_3 and 2,4-DNP were Na^+-K^+ ATPase inhibitors. As shown in Fig. 4, TFT uptake significantly decreased under Na^+-free conditions and was strongly inhibited by the addition of thymidine, uridine, NaN_3, and 2,4-DNP.

Uptake of TFT by *Xenopus laevis* oocytes

To confirm that transport mediated by carrier proteins plays a role in TFT uptake in the small intestine, uptake studies using *Xenopus laevis* oocytes injected with small intestinal total RNA were conducted. Figure 5 shows the results of experiments measuring TFT uptake into oocytes injected with total RNA prepared from rat small intestine. TFT uptake by *Xenopus laevis* oocytes injected with rat small intestine total RNA was 5 times greater than that by water-injected oocytes; uptake after addition of 1 mM thymidine was significantly lower than that in water-injected oocytes. This suggested that nucleoside transporters could play a role in the uptake of TFT in the rat small intestine.

To investigate the roles of rCNT1and rCNT2 in TFT uptake, uptake assays were conducted using *Xenopus laevis* oocytes injected with rCNT1 cRNA or rCNT2 cRNA. Figure 6 shows the results of experiments measuring the uptake of thymidine and TFT in the oocytes injected with rCNT1 cRNA and water. TFT uptake into oocytes injected with rCNT1 cNRA was significantly greater than that into oocytes injected with water, and uptake of TFT by oocytes injected with rCNT1 was comparable to that of oocytes injected with thymidine. Figure 7 shows the results of the experiments measuring the uptake of inosine or TFT in oocytes injected with rCNT2 cRNA. Uptake of inosine, the endogenous substrate for rCNT2, by *Xenopus* oocytes injected with rCNT2 cRNA was significantly greater than that by water-injected oocytes, but TFT uptake of both groups of oocytes was the same.

Moreover, kinetic analysis of the concentration-dependent profile of the uptake velocity by oocytes injected with rCNT1 cRNA is shown in Fig. 8, and the estimated Km value of TFT uptake mediated by rCNT1 was 26.9 μM. The inhibitory effects of thymidine and inosine on TFT uptake by *Xenopus* oocytes injected with rCNT1 was investigated; TFT uptake was strongly inhibited by thymidine, but not by inosine (Fig. 9).

Estimation of TFT absorption by using the *in situ* single-pass perfusion technique

To confirm the contribution of rCNT1 in the intestinal absorption of TFT, the inhibitory effect of thymidine on TFT uptake was estimated using the *in situ* single-pass perfusion method. As shown in Fig. 10, the values of Peff in the absence and presence of thymidine were 1.02×10^{-4} cm/sec and 0.54×10^{-4} cm/sec, respectively. The value of Peff significantly decreased to about 50 % after addition of 1 mM thymidine.

Discussion

TFT is a pyrimidine nucleoside analogue currently being developed as an oral anticancer agent in combination with TPI. In the present study, we characterized the membrane carrier protein of TFT and determined the contribution of the carrier protein on the small intestinal absorption of TFT in rats.

Although TFT was well absorbed in rats (>75% of the dose) after oral administration, the TFT uptake by the everted sacs was in a concentration-dependent saturable manner, suggesting that some active transport system may play a role in the small intestinal absorption of TFT. Further, CNTs were thought to be involved in TFT absorption in small intestinal tissues of the rat because TFT was taken up by the everted sacs of the small intestine via a sodium-dependent mechanism; further, thymidine, which is a substrate for rCNTs, strongly inhibited the uptake of TFT into small intestinal tissues of everted sacs and into *Xenopus laevis* oocytes injected with total RNA of the rat small intestine. A previous report (Hong, 2004) indicated that rCNT1 and rCNT2 mRNAs were predominantly expressed in the small intestine of rats, but rCNT3 mRNA was not detected; therefore, we performed uptake assays using *Xenopus laevis* oocytes injected with rCNT1 cRNA and rCNT2 cRNA to investigate the substrate specificity of TFT for these intestinal transporters. Our

results showed that TFT is a preferred substrate for rCNT1 not for rCNT2. Furthermore, to investigate the contribution of rCNT1 in small intestinal absorption of TFT in rats, we performed *in situ* single-pass perfusion experiments using thymidine as an inhibitor of rCNT1. TFT uptake into the small intestinal tissues significantly decreased to about 50 % after addition of 1 mM thymidine. This result suggested that rCNT1 contributes to TFT absorption in the small intestinal lumen. Although the inhibitory effect of thymidine in *in situ* single-pass perfusion experiments is comparable to that in everted sac experiments, the inhibitory effect of thymidine was different from that in uptake assay using *Xenopus laevis* oocytes injected with rCNT1 cRNA. Therefore, other transport systems such as either other transporters or passive diffusion might be involved in the small intestinal absorption of TFT in rats.

Because CNT1 has a wide distribution in various mammalian tissues and cancer cells (Pennycooke, 2001; Hong Lu, 2004; Govindarajan, 2007), it might be involved not only in the pharmacokinetics but also in the anticancer effect and adverse effects of TFT. Nucleoside transporters have been reported to be involved in the clinical and adverse effects of nucleoside analogues drugs. For instance, a previous report suggested that the mitochondrial toxicity of the antiviral drug fialuridine, a substrate for ENT1, was closely related to ENT1 expression in the

mitochondrial membrane (Lai Y, 2004). A nucleoside transporter has been reported to be involved in the antitumor effect of gemcitabine (Achiwa, 2004), and pancreatic adenocarcinoma patients with high hENT1 and hCNT3 protein expression exhibit significantly longer survival after adjuvant gemcitabine-based chemotherapy (Maréchal, 2009). Biomarkers such as hCNT3 and hENT1 should be prospectively evaluated in patients receiving gemcitabine-based adjuvant therapy. In addition, in Waldenstrom's macroglobulinemia and small lymphocytic lymphoma, the patients with low levels of hCNT1 expression showed inferior clinical response to 2-chloro-2'-deoxyadenosine (2-CdA)-based therapy, and the level of hCNT1 expression was suggested to be useful in predicting the response to nucleoside analogs such as 2-CdA known to be taken up via hCNT1 (Rabascio, 2010). In this study, we found that TFT is a preferred substrate for rCNT1. TFT could be a substrate for hCNT1 because rCNT1 and hCNT1 are homologous (Ritzel, 1997).

Granulocytopenia was the main adverse effect in humans after oral administration of a combination of TFT and TPI (Hong, 2006). The expression of hCNT1 in bone marrow-derived cells was confirmed (Rabascio, 2010), and hCNT1 may be involved in the adverse effects of TFT. Thus, CNT1 might be involved in not only the anticancer effect but also the adverse effects of TFT in humans. Our results indicate the potential of CNT1 as a biomarker of TFT in clinical trials.

In conclusion, we showed that TFT is well absorbed after oral administration, TFT is the preferred substrate for rCNT1, and CNT1 clearly plays a role in TFT absorption in the intestinal lumen of rats.

Acknowledgments

The authors thank former Professor Akira Tsuji in the Graduate School of Natural Science and Technology and Professor Yukio Kato in Pharmaceutical and Health Sciences at Kanazawa University for their technical expertise.

Authorship Contributions

Participated in research design: Okayama, Yoshisue, Kuwata, Komuro, Nagayama

Conducted experiments: Okayama, Yoshisue, Kuwata

Performed data analysis: Okayama

Wrote or contributed to the writing of the manuscript : Okayama, Yoshisue, Ohta

References

Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R (2004), Determinants of sensitivity and resistence to gemcitabine : the roles of human equilibrative nucleoside transporter 1 and deoxycitidine kinase in non-small cell lung cancer. Cancer Sci. 95 (9):753-757

Amidon GL, Lennernas H, Shah VP, Crison JR (1995), A theoretical basis for a biopharmaceutic drug classification : the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res.12(3):413-420

Ansfield FJ, Ramirez G (1971), Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep 55(2):205-208

Dexter DL, Wolberg WH, Ansfield FJ, Helson L, Heidelberger C (1972), The Clinical Pharmacology of 5-Trifluoromethyl-2'-deoxyuridine. Cancer Research 32:247-253

Emura T, Suzuki N, Yamaguchi M, Ohshimo H and Fukushima M (2004), A novel combination antimetabolite, TAS-102 exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25(3):571-578

Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, Unadkat JD (2007) In situ hybridization and immunolocalization of concentrative and

equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, 1809–1822

Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM (2006) Phase 1 study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.Cancer 107(6), 1383-1390

Hong L, Chuan C and Curtis K (2004) Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metab Dispos. 32 (12), 1455-1461

Kato T, Hayashi Y, Inoue K and Yuasa H (2004) Functional Characterization of the Carrier-Mediated Transport System for Glycerol in Everted Sacs of the Rat Small Intestine. Biol. Pharm. Bull. 27(11) 1826-1830

Lai Y, Tse CM, Unadkat JD (2004), Mitochondrial expression of the human equilibrative nucleoside transporter 1(hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J. Biol. Chem. 279(6):4490-7

Lang TT, Selner M, Young JD, Cass CE (2001) Acquisition of human concentrative nucleoside transporter 2 (hCNT2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Mol Pharmacol. 60(5):1143-1152

Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA,Cass CE, Young JD(1999) Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst. 91(21):1876-1881

Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J, Van Laethem JL (2009) Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 15(8):2913-9

Mori N, Yokooji T, Kamio Y, Murakami T (2008) Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats. European Journal of Pharmacology(586), 52-58

Nakashima E, Tsuji A (1985) Mutual effects of amino-beta-lactam antibiotics and glycylglycine on the transmural potential defference in the small intestinal epithelium of rats. J Pharmacobiodyn.8:623-632

Okada M, Suzuki K, Nakashima M, Nakanishi T, Fujioka N (2006) The nucleotide derivatives inosine and inosinic acid inhibit intestinal absorption of mizoribine in rats. Eur. J. Pharmacol. 531,140-144

Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL (2008) Phase 1 clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 26(8):794-799

Patil SD, Ngo LY, Glue P, Unadkat JD (1998) Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm.Res. 6, 950-962

Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR(2001) Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun, 280(3), 951-959

Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G (2010) Expression of the human concentrative nucleoside transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Wadenstrom's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leuk Res 34(4), 454-457

Ritzel MW, Yao SY, Huang MY, Elliott JF, Cass CE, Young JD (1997) Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter(hCNT1).Am J Physiol.272, 707-714

Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, Ritzel R, Mowles DA, Carpenter P, Chen XZ, Karpinski E,Hyde RJ, Baldwin SA, Cass CE, Young JD (2001) Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside transporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem. 276(4) : 2914-2927

Smith KM, Slugoski MD, Loewen SK, Ng AM, Yao SY, Chen XZ, Karpinski E, Cass CE, Baldwin SA, Young JD (2005) The broadly Selective Human Na_/Nucleoside Cotransporter (hCNT3) Exhibits Novel Cation-coupled Nucleoside Transporter Characteristics. J. Biol. Chem. 280(27):25436-25449

Temmink OH, de Bruin M, Comijn EM, Fukushima M, Peters GJ (2005) Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. Anticancer Drugs 16(3):285-292

Figure legends.

Fig.1 Structure of TFT and TPI

Fig. 2 Concentration of TFT in the plasma after single oral administration of (50 mg/kg ^{14}C-TFT + 23.6 mg/kg TPI) to fasting male rats. Data represent the mean (SD) (n = 4).

Fig. 3 Concentration-dependent uptake of TFT in everted sacs of the rat intestine. TFT uptake was evaluated for 1 min at 37°C; TFT concentration ranged from 10 μM to 5 mM. Michaelis–Menten plot (a) and Eadie–Hofstee plot (b) analysis for TFT uptake in the everted sacs. Data represent the mean (SD) (n = 3).

Fig. 4 Inhibitory effect of Na^+, thymidine, uridine, 2, 4-DNP, and NaN_3 on TFT uptake in the everted sacs of the rat intestine. The uptake of TFT (100 μM) was evaluated for 1 min at 37°C. Na^+-free buffer contained 118 mM choline chloride and 25 mM choline bicarbonate instead of NaCl and $NaHCO_3$, respectively. Control value means uptake clearance of TFT in test solution prepared from Krebs buffer containing Na^+. Data represent the mean (SD) (n = 3). **, $p < 0.01$,

and ***, $p < 0.001$ compared with control. 2, 4-DNP: 2,4-dinitrophenol, NaN_3: sodium azide.

Fig. 5 TFT uptake by *Xenopus laevis* oocytes injected with total RNA of rat small intestines. *Xenopus laevis* oocytes were injected with 50 nL of nuclease-free water or total RNA (200 ng/oocyte) solution. Uptake of ^{14}C-TFT (8 μM) was evaluated for 60 min at 25°C. Data represent the mean (SEM) (n = 3). In the experiment, 1 mM of thymidine was used as an inhibitor. **, $p < 0.01$.

Fig. 6 TFT uptake by *Xenopus laevis* oocytes injected with rCNT1 cRNA. *Xenopus laevis* oocytes were injected with 50 nL of nuclease-free water or rCNT1 cRNA (25 ng/oocyte). The uptake of ^{14}C-thymidine (8 μM) and ^{14}C-TFT (6 μM) were evaluated for 30 min at 25°C. Data represent the mean (SEM) (n = 3~4). *, $p< 0.05$ and **, $p < 0.01$ compared with water.

Fig. 7 TFT uptake by *Xenopus laevis* oocytes injected with rCNT2 cRNA. *Xenopus laevis* oocytes were injected with 50 nL of nuclease-free water or rCNT2 cRNA (25 ng/oocyte). The uptake of ^{14}C-inosine (8 μM) and ^{14}C-TFT (7 μM) were evaluated for 30 min at 25°C. Data

represent the mean (SEM) (n = 3~4). **, $p < 0.01$ compared with water.

Fig. 8 Concentrations-dependent uptake of TFT by *Xenopus laevis* oocytes injected with rCNT1 cRNA. *Xenopus laevis* oocytes were injected with 50 nL of rCNT1 cRNA (25 ng/oocyte). The uptake of ^{14}C-TFT was evaluated for 20 min at 25°C. Data represent the mean (SD) (n = 6~8). The Km value of TFT for rCNT1 was calculated by Multi (Microsoft Excel program).

Fig. 9 Inhibitory effects of thymidine and inosine on TFT uptake by *Xenopus laevis* oocytes injected with rat CNT1. *Xenopus laevis* oocytes were injected with 50 nL of rCNT1 cRNA (25 ng /oocyte). The uptake of ^{14}C-TFT (8 μM) was evaluated for 20 min at 25°C. Data represent the mean (SD) (n = 5~6). ***, $p < 0.001$ compared with control. The uptake clearance of TFT in the absence of inosine and thymidine was used as control values.

Fig. 10 Inhibitory effect of thymidine on TFT uptake based on the *in situ* single-pass perfusion method. The uptake of TFT (0.4 μM) from rat small intestine was evaluated at 37°C. Data represent the mean (SEM) (n = 3). The value of control was Peff of 0.4 μM TFT in the absence of

thymidine. *,$p < 0.05$ compared with control value.

Table

Excretion of radioactivity (% of dose)				
Time (hr)	Urine	Feces	Expired air	Total
0-24	59.8 ± 4.7	19.7 ± 2.8	15.6 ± 2.5	95.0 ± 1.1

Table 1. Cumulative excretion of radioactivity in the urine, feces, and expired air as $^{14}CO_2$ after single oral administration of (50 mg/kg ^{14}C-TFT and 23.6 mg/kg TPI) to non-fasting male rats.

Data represent the mean (SD) (n = 4)

Figure 1

TFT

TPI

Figure 2



Figure 3 a)



Figure 3 b)



Figure 4



Figure 5



Figure 6



Figure 7



Figure 8



Figure 9



Figure 10